<DOC>
	<DOCNO>NCT00001035</DOCNO>
	<brief_summary>To investigate toxicity interferon alfa-2b ( IFN alfa-2b ) combination nucleoside analog therapy HIV-positive patient chronic hepatitis C. To determine efficacy treatment IFN alfa-2b chronic hepatitis C patient advance HIV infection treat nucleoside analog therapy . IFN alfa-2b HIV inhibitory property also approve treatment chronic hepatitis C. Studies show IFN alfa-2b effective asymptomatic HIV-positive patient chronic hepatitis C , drug 's benefit hepatitis C patient advance HIV infection determine .</brief_summary>
	<brief_title>The Safety Effectiveness Two-Drug Combination Treatment Patients With Hepatitis C Plus Advanced HIV Infections</brief_title>
	<detailed_description>IFN alfa-2b HIV inhibitory property also approve treatment chronic hepatitis C. Studies show IFN alfa-2b effective asymptomatic HIV-positive patient chronic hepatitis C , drug 's benefit hepatitis C patient advance HIV infection determine . Patients receive interferon alpha-2b subcutaneously 3 time weekly 6 month . If response see 18 week therapy initial response follow relapse therapy , dose increase . Patients require dose escalation continue IFN alfa-2b additional 6 month . All patient also receive available nucleoside analog therapy ( zidovudine , didanosine , zalcitabine ) currently accept dos clinically appropriate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Treatment suppression opportunistic infection standard drug . Pneumovax , HIB , tetanus , influenza , hepatitis B vaccine . Clinically indicated antibiotic . Short course steroid ( &lt; 21 day ) acute problem related hepatitis C. Other regularly prescribe medication analgesic , nonsteroidal antiinflammatory agent , antipyretic , allergy medication , oral contraceptive . Patients must : HIV positivity . Documented hepatitis C virus . CD4 count &lt; = 200 cells/mm3 . No severe liver disease ( Grade C ChildsPugh classification ) chronic liver disease cause hepatitis C. Willingness follow duration treatment followup period . Prior Medication : Allowed : Prior AZT , ddI , ddC . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Hepatitis B ( HBsAg positive ) . Autoimmune hepatitis ( FANA titer &gt; = 1:160 antismooth muscle antibody titer &gt; = 1:160 ) . Wilson 's disease . alpha1 antitrypsin deficiency . Hemochromatosis . Malignancy require systemic chemotherapy . Concurrent Medication : Excluded : Nonnucleoside analog therapy HIV . Biologic response modifier . Systemic cytotoxic chemotherapy . Chronic systemic steroid use . Concurrent Treatment : Excluded : Radiation therapy local irradiation skin . Prior Medication : Excluded : Prednisone within 12 week prior study entry ( patient receive prior daily dos 1 month long duration ) . Acute therapy infection within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>